Courtesy of Benzinga.
Bernstein downgraded Johnson & Johnson (NYSE: JNJ) on Wednesday to Market Perform.
The stock was down more than 2 percent at $104.08.
On Tuesday, Johnson & Johnson announced it was buying biotech company Alios BioPharma for $1.75 billion.
Johnson & Johnson will have its Q3 earnings release on October 14.
Latest Ratings for JNJ
Date | Firm | Action | From | To |
---|---|---|---|---|
Oct 2014 | Bernstein | Downgrades | Market Perform | |
Aug 2014 | Jefferies | Maintains | Hold | |
Jul 2014 | Citigroup | Maintains | Buy |
View More Analyst Ratings for JNJ
View the Latest Analyst Ratings
Posted-In: Sanford C. Bernstein & CoDowngrades Analyst Ratings